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Background: Topical hemostatic agents are used to reduce bleeding and transfusion need during cardiothoracic
surgery. We report our experience with Arista® AH Absorbable Hemostatic Particles (Arista® AH), a novel plant-based
microporous polysaccharide hemostatic powder.
Methods: Data were retrospectively collected for patients (n = 240) that received cardiothoracic surgery at our
institution from January 2009 to January 2013 with (n = 103) or without (n = 137) the use of Arista® AH. Endpoints
included protamine to skin closure time (hemostasis time), cardiopulmonary bypass time, quantity of Arista® AH
applied, intraoperative blood product usage, intraoperative blood loss, chest tube output 48 hours postoperatively,
blood products required 48 hours postoperatively, length of stay in the intensive care unit, 30-day morbidity, and
30-day mortality.
Results: 240 patients (176 M: 64 F) underwent 240 cardiothoracic procedures including heart transplantation
(n = 53), cardiac assist devices (n = 113), coronary artery bypass grafts (n = 20), valve procedures (n = 19), lung
transplantation (n = 17), aortic dissection (n = 8), and other (n = 10). Application of Arista® AH led to significant
reduction in hemostasis time versus the untreated control group (Arista® AH: 93.4 ± 41 min. vs. Control: 107.6 ±
56 min., p = 0.02). Postoperative chest tube output in the first 48 hours was also significantly reduced (Arista®
AH: 1594 ± 949 mL vs. Control: 2112 ± 1437 mL, p < 0.001), as well as transfusion of packed red blood cells (Arista®
AH: 2.4 ± 2.5 units vs. Control: 4.0 ± 5.1 units, p < 0.001). There was no significant difference in 30-day mortality or
postoperative complications.
Conclusion: Use of Arista® AH in complex cardiothoracic surgery resulted in a significant reduction in hemostasis
time, postoperative chest tube output, and need for postoperative blood transfusion.
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Postoperative bleeding complications are associated with
poorer outcomes in cardiac surgery and contribute to
excessive overall healthcare costs. The need for intraop-
erative and postoperative blood products are also associ-
ated with potential risks including adverse reactions,
transfusion related injury, or infectious transmissions
that are significant factors for morbidity or mortality [1].
In their study examining open heart procedures requir-
ing re-exploration for bleeding, Hall et al. described that* Correspondence: BAbruckner@houstonmethodist.org
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unless otherwise stated.66% of cases were from surgical bleeding versus 34% at-
tributed to coagulopathy where no surgical bleeding site
was found [2].
Bleeding arises as a result of several aspects inherent to
these cardiac procedures, including placement of cardiac
suture lines in great vessels or chambers of the heart, as
well as creation of high pressure anastomoses. Even greater
challenges exist during re-operative procedures as patients
present to the surgeon on aspirin, other platelet-inhibiting
drugs, heparin, and oral anti-coagulants including Couma-
din. Heparinization for cardiopulmonary bypass, coagulop-
athy from extracorporeal membrane oxygenation, and
hypothermia may also present an even greater challenge toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study design.
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from inadequate hemostasis may necessitate higher trans-
fusion rates of blood products [4].
Used as an adjuvant measure in the operating room,
topical hemostatic agents have been developed to aid in
blood loss reduction within the surgical field, which may
also reduce overall bleeding in the postoperative period.
It is important to delineate differences in the commercially
available surgical sealants and broad field hemostatic
agents. Sealants are typically employed to anastomotic
suture lines prior to removal of clamps as a preventative
measure. Topical hemostatic agents are usually applied to
the bleeding area and pressure is applied to promote clot-
ting and stop active bleeding. An ideal agent would be one
that has the ability to control both types of bleeding, while
not posing adverse effects attributed to its application.
Arista® AH (C. R. Bard, Inc. – Davol, Warwick, RI) is a
microporous polysaccharide hemosphere (MPH) powder
derived from a biologically inert plant source that can be
administered to the entire surgical field [5]. It absorbs water
and low molecular weight compounds from the blood to
concentrate platelets and clotting proteins at its beaded
surface while enhancing endogenous clotting processes. It
has not only been used in cardiothoracic surgery, but also
in general, urology and otolaryngology surgical procedures.
The aim of this retrospective study was to evaluate all of
the cardiothoracic surgical procedures conducted at a sin-
gle center in which Arista® AH was used, as compared to
an untreated control population, and to analyze the follow-
ing endpoints: protamine to skin closure time (hemostasis
time), cardiopulmonary bypass time, the quantity of Arista®
AH applied, use of intraoperative blood products, intraop-
erative blood loss, chest tube output at 48 hours postopera-
tively, blood products required at 48 hours postoperatively,




This study was approved by the institutional review
board at the Houston Methodist Hospital, and patient
confidentiality was insured. This retrospective data col-
lection study was designed to gather information from
all patients that underwent complex cardiothoracic
surgical interventions (cases requiring the use of cardio-
pulmonary bypass) from January 2009 to January 2013
at the Houston Methodist Hospital (HMH). Sample size
for this retrospective analysis was 240 patients. Specific-
ally, we compared 103 patients that received Arista® AH
(January 2011 to January 2013) to 137 patients that did
not receive Arista® AH (January 2009 to January 2011)
(Figure 1). Subjects were identified in one of two ways:
1. Directly from our practice or inpatient data, or 2.
Review of medical records within the HMH-MedicalCenter inpatient list (MethOD) or archived medical re-
cords. All surgeries over the study period were per-
formed by two experienced cardiothoracic surgeons with
5+ years of experience post-fellowship starting in 2009.
Additionally, during the study period, there were no major
changes in technique or protocol in the way operations
were conducted, with the exception of topical hemostatic
agent choice which occurred in 2011. Complex cardio-
thoracic surgical procedures included: left, right, or biven-
tricular assist device implantation or explantation, heart
transplantation, double lung transplantation requiring
cardiopulmonary bypass, aortic reconstructions, coronary
artery bypass, and aortic or mitral valve replacements. All
patients in the treated and control group received a seal-
ant on aortic or ventricular suture lines, which is standard
in our surgical practice. Additionally, it has been our sur-
gical practice following cardiopulmonary bypass cases (all
cases included in this study) to apply a topical hemostatic
agent as well. Starting in 2011 (the treated group), we only
used Arista® AH as a topical hemostatic agent. Further-
more, no significant practice changes were made during
the study period as it relates to use of preoperative antico-
agulants/procoagulants and perioperative transfusion trig-
gers. The historical control patients from 2009 to 2011
received at least one hemostatic agent FloSeal® (Baxter
International, Inc., Deerfield, IL), Gelfoam® with thrombin
(Baxter International, Inc., Deerfield, IL), or Surgicel®
(Ethicon, Inc., Bridgewater, NJ) without Arista® AH.
Data collection
All patient records were stratified by age, sex, and complex
cardiothoracic surgical procedure. Endpoints evaluated
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cardiopulmonary bypass time, the quantity of Arista® AH
applied, use of intraoperative blood products, intraoperative
blood loss, chest tube output at 48 hours postoperatively,
blood products required at 48 hours postoperatively, length
of stay in the intensive care unit, 30-day morbidity and
30-day mortality. Morbidity included ventilator depend-
ence (vent requirement >7 days), shock (requiring 2 or
more pressors with hypotension), renal failure (new onset
requiring dialysis), sepsis (positive blood cultures and
hypotension), and stroke (verified by CT scan or MRI scan).
Scanning electron microscopy (SEM)
To gain visual evidence of the Arista® AH hemostatic
mechanism of action, high vacuum SEM was performed
on mediastinal clot samples taken from two patients that
received Arista® AH. These specimens were obtained
from patients intraoperatively, ten minutes after the ad-
ministration of Arista® AH, and then processed histologi-
cally. Specimens were fixed in glutaraldehyde for further
analysis. The specimens were subsequently fixed in os-
mium and coated in gold before undergoing evaluation
by SEM, which included acquiring photomicrographs at
low and high magnification (up to 1900×) for visual
microscopic assessment.
Surgical technique
All operations were performed through full median ster-
notomy except for lung transplantations, which were per-
formed through a clamshell incision. Heparinization for
cardiopulmonary bypass was instituted and was reversed
by protamine sulfate after weaning from extracorporeal
circulation. Among the Arista® AH group patients, Arista®
AH (5 gram size) was immediately applied following pro-
tamine administration to the entire operative field to ad-
dress all instances of active bleeding (pulsatile flow,
continuous flow, or oozing after application of conven-
tional means including direct pressure, electrocautery, and
suture ligation). The number of Arista® AH (5 gram size)
applications was dependent upon bleeding and at the
discretion of the practicing surgeon. In Figure 2, the intra-
operative technique of administration of Arista® AH is
demonstrated in a patient that underwent redo aortic
valve replacement. Our Arista® AH application technique
is to apply the device to the entire surgical field as a broad
field hemostatic agent.
Statistical methods
Data were retrospectively entered in a computerized
database and analyzed through SPSS software version
11.0.1 for Windows (SPSS Inc, Chicago, IL) under the
guidance of a departmental statistician. Continuous data
is presented as the mean +/− standard deviation and
compared through the Student t test assuming unequalvariances. One-way analysis of variance (ANOVA) was
employed to disclose significant differences among base-
line variables. Categorical data are given as percentages
and compared through the Chi Squared test. Tests were
two-tailed and Yates correction was applied. Inter-group
comparisons were performed in the Arista® AH group by
comparing the amount of product used to the data end
points using a two sample Wilcoxon Rank Sum Test.
Results
Patient population
There was no significant difference in preoperative char-
acteristics (age, sex, procedure type) between the two
groups (Table 1). Average patient age in the Arista® AH
group was 55 ± 12.6 years (range 15–80) vs. 56 ±
13.7 years (range 20–83) in the control group. Both
groups had significantly more men than women, and
procedure breakdown was similar with cardiac assist
devices and heart transplantations as the most common
procedure in both groups.
Endpoints
Intraoperatively (Table 2), there was a significant differ-
ence in protamine to skin closure time (hemostasis time)
in the Arista® AH group vs. the control group (p = .02).
There was no significant difference in cardiopulmonary
bypass time between the Arista® AH and control group
or intraoperative blood product usage. Estimated blood
loss was less in the Arista® AH group compared to the
control group, but not statistically significant (p = .08).
Chest tube output 48 hours postoperatively was signifi-
cantly less in the Arista® AH group compared to the
control group (p < 0.001) as well as PRBC transfusion
requirement (p < 0.001) (Table 3). PRBC transfusion re-
quirement was further stratified into need for 1–2 units
versus 3 or more units. The control group had a higher
percentage of patients (41% vs 34%) requiring 1–2 units
and both groups had similar numbers of patients requir-
ing 3 or more units (33% vs 36%) in the first 48 hours
following surgery. The Arista® AH group also required
fewer platelets and FFP, but these values were not statis-
tically significant. There was no significant difference in
ICU stay, mortality (Table 3) or morbidity (defined as
ventilator dependence, shock, renal failure, sepsis, or
stroke) between the groups (Table 4). Additionally, there
was no statistical difference between the two groups in
overall rate of unplanned re-exploration for bleeding
(<24 hrs).
Intraoperative specimens of Arista® AH treated areas
were obtained from the mediastinum of two patients
who underwent LVAD implantation. These mediastinal
clot specimens were obtained 10 minutes after the
administration of Arista® AH as a broad field hemostat
to the surgical field (Figure 3). Inspection of these high
Figure 2 Intraoperative photographs from a patient undergoing a redo aortic valve replacement procedure. A) the surgical procedure is
complete, including administration of protamine and removal of cannulae. B) Arista® AH is applied within the surgical field to areas of active
bleeding as a broad field hemostat.
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interacting and appear to be “concentrating” the sur-
rounding blood and clotting components. Additional
investigative microscopy will be needed in future studies
of Arista® AH to provide further clinical validation of the
topical hemostatic mechanism of action.
Discussion
The primary objective of this study was to evaluate the
use of Arista® AH as a topical hemostatic agent in com-
plex cardiothoracic surgical procedures requiring cardio-
pulmonary bypass in our surgical practice. Arista® AH
was applied as a broad field hemostat to the surgical
field to control active bleeding. To our knowledge,







Age (yrs.) 55 ± 12.6 (15–80) 56 ± 13.7 (20–83) NS
Sex (M/F) 79/24 97/40 NS
Heart transplant 27 26 NS
Cardiac assist devices 52 61 NS
CABG 5 15 NS
Valve procedure 5 14 NS
Lung transplant 8 9 NS
Aortic dissection 2 6 NS
Other* 4 6 NS
*Mediastinal explorations, LV aneurysm repairs.use of Arista® AH is the largest case series reported for
patients undergoing cardiothoracic procedures to date.
Our results demonstrated improved hemostasis with
respect to hemostasis time, chest tube output, and need
for PRBC transfusion in the first 48 hours postopera-
tively. However, we do acknowledge that chest output in
the first 8–12 hours may be more meaningful as it re-
lates to post-operative bleeding and there may be a
serous component after 24–48 hours. Due to the retro-
spective nature of our study and availability of data,
chest tube output was recorded at least on a 24 hour
basis and earlier drainage was not available in all
patients. Postoperative bleeding complications in cardiac
surgery can have multiple etiologies. Invasiveness of the
procedure, induced hypothermia, extended use of CPB,
and increasing age, are major reasons for increased
blood loss and the higher incidence of blood transfu-
sions [6]. Concomitant postoperative complications, such
as stroke, renal dysfunction, and systemic inflammatory
response syndrome (SIRS) also increase incidence of post-
operative bleeding [7]. Topical hemostatic agents are
valuable adjuncts to cardiothoracic surgical procedures
because they can decrease intraoperative bleeding, and
may reduce the need for postoperative blood transfusion.
In their study of 1,118 patients, Christensen et al. demon-
strated that average hospital costs were substantially
related to excessive postoperative hemorrhage in cardiac
surgery [8]. Also in their study, postoperative bleeding was
a significant risk factor for morbidity and mortality. Clin-
ical interventions that can effectively prevent or address
excessive postoperative hemorrhage in cardiac surgery
are likely to have substantial cost-effectiveness potential.
Table 2 Intraoperative variables
Characteristic Arista® AH (n = 103) Control (n = 137) p-value
Protamine to skin closure (min) 93.4 ± 41 107.6 ± 56 0.02
CPB time (min) 114.3 ± 73 111.3 ± 77 0.76
Arista applied (5 g applications) 2.5 ± 1.7 (range 1–11) N/A –
Intraop EBL (mL) 1719 ± 1209 2024 ± 1503 0.08
Intraop PRBCs (units) 2.9 ± 2.9 2.9 ± 3.2 0.9
Intraop FFP (units) 2.5 ± 3 2.9 ± 2.8 0.28
Intraop platelets (units) 2.2 ± 2.5 2.2 ± 2.9 0.83
PRBC = Packed red blood cells; CPB = cardiopulmonary bypass; EBL = estimated blood loss; FFP = fresh frozen plasma.
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excessive postoperative hemorrhage died compared with
6% of the patients without excessive postoperative
hemorrhage (p < .0001). The potential to reduce postoper-
ative bleeding, improve outcomes, and effectively reduce
operative time/overall healthcare costs are major reasons
that topical hemostatic agents are increasingly being used
across all surgical disciplines. Although our study did not
seek cost analysis, our data suggest that improved opera-
tive time and postoperative bleeding outcomes may trans-
late into reduced healthcare costs. Additionally, although
there was a decrease in transfusion requirements in the
immediate postoperative period in the treated group, this
did not translate into lower morbidity or mortality in this
group, however larger numbers of treated patients in a
future prospective trial may show significance in this very
important area.
In a comprehensive review summarizing the efficacy of
current topical agents, Barnard and colleagues con-
cluded that bleeding during re-do sternotomy and the
need for multiple blood transfusions resulted in poorer
outcomes [6]. According to Barnard, “The ideal topical
hemostatic agent would be one that is deployable even
against brisk hemorrhage, which is independent of native
clotting mechanisms and would not pass through
salvage filtration systems while not being sourced fromTable 3 Postoperative outcomes
Characteristic Arista® AH (n = 1
CT output 48 hrs postop (mL) 1594 ± 949
PRBCs 48 hrs postop (units) 2.4 ± 2.5
-Patients received 1–2 units 35 (34%)
-Patients received ≥3 units 34 (33%)
ICU platelets 48 hrs postop (units) 1.2 ± 2.3
ICU FFP 48 hrs postop (units) 1.2 ± 2.6
ICU stay (median days) 8(range 2–37)
30 day mortality, (%) 17.5%
CT = chest tube; PRBC = Packed red blood cells; CPB = cardiopulmonary bypass;
care unit.bovine or human origin”. In the current study, we demon-
strated the safety and effectiveness of Arista® AH in
cardiothoracic surgical procedures, and did not observe
any adverse effects or reactions associated with its use. In
a small case series, Tschan et al. demonstrated the safety
of Arista® AH when employed in neurosurgery [9]. In their
study, Arista® AH was used as an adjuvant hemostatic
agent in 33 brain tumor resections. Hemostasis was
achieved in 57 seconds on average. Moreover, at 3 months
there was no product related neurological or embolic
complications.
For ventricular assist device procedures, we leave the
chest open for 24 hours after surgery and return the
following day for washout and closure. For each of these
cases, no Arista® AH was identified by visual inspection
during 24 hours following the initial procedure. Accord-
ing to Hamdi, MPH is enzymatically degraded into water
soluble fragments, leaving no trace of foreign material in
as little as 12 hours, with a stable intact clot remaining
[10]. In his work with thromboelastography, Dong states
that the clot formed with expanded MPH beads, plate-
lets, and clotting proteins has been shown to be more
robust than a purely natural clot [11].
Prior to experience with Arista® AH in 2011, it was
our surgical practice to use a topical hemostatic agent
which included Gelfoam® and thrombin, Surgicel®, or03) Control (n = 137) p-value
2112 ± 1437 <0.001
4.0 ± 5.1 <0.001
56 (41%) –
49 (36%) –
1.8 ± 3.4 0.10
1.9 ± 3.7 0.12
9(range 2–57) 0.08
16.1% NS
EBL = estimated blood loss; FFP = fresh frozen plasma; ICU = intensive






Ventilator dependence 21(20.4%) 33(24.1%) NS
Shock 16(15.5%) 21(15.3%) NS
Renal failure 17(16.5%) 23(16.8%) NS
Sepsis 2(1.9%) 2(1.5%) NS
Stroke 5(4.9%) 5(3.6%) NS
Unplanned re-exploration (<24 hrs) 6(5.8%) 9(6.6%) NS
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plex cardiothoracic procedures requiring cardiopulmo-
nary bypass, we observed noticeable decreases in chest
tube output and blood product transfusions in most
of our patients. In addition, we noticed that we were
spending less time in the operating room for hemostasis.
From these earlier experiences with Arista® AH, we essen-
tially changed our approach to surgical field hemostasis
and started using only Arista® AH as our topical hemostatic
agent (2011-present). In our current surgical practice for
nearly every case, we also selectively use a sealant (CoSeal)
on anastomotic suture lines, and after protamine adminis-
tration, apply Arista® AH as a broad field hemostatic agent.
Studies have revealed the use of effective surgical sealants
for hemostasis at anastomoses and suture lines, and
our study is not the first to investigate the potential of
hemostatic adjuncts [12]. For example, Floseal® has been
shown to reduce transfusions and post-operative bleeding
in cardiac surgery [13]. However, there may be concerns
with the use of Floseal® including cost, the biologic compo-
nent exposure (thrombin), and its compatibility with cell
salvage systems. We feel that the hemostatic agents we
were using prior to Floseal® were more “localized” field
hemostatic agents and the ability to broadly cover the
surgical field was limited. We consider Arista® AH a “broad
field” hemostatic agent, as it can be used to cover largeFigure 3 Scanning Electron Microscopy (SEM) of Arista® AH post-appl
adhering to the Arista® AH polysaccharide hemosphere. A) Low magnificatareas within the surgical field. By broadly covering the sur-
gical field with Arista® AH (a white powder), we were also
able to identify additional localized areas of bleeding that
potentially require additional suture placement. Therefore,
with its ease of use and application, it can be readily avail-
able and deployed by the surgeon and operating room
staff, especially when time is of the essence, and patients
are bleeding.
In addition to complex cardiothoracic cases, Arista®
AH has been used in the fields of obstetrics/gynecology,
urology, otolaryngology, and general sugery, and has
been shown to reduce intraoperative bleeding [14-17].
The big advantages of Arista® AH is that it appears to be
safe and effective across multiple surgical disciplines, is
completely absorbed in 24–48 hours, and contains no
human or animal components. Furthermore, it does not
appear to represent a nidus for infection or granuloma
formation, and no adverse events have been reported in
clinical studies or even in our own clinical experience
[9,14,16].
Limitations
There are important limitations that should be acknowl-
edged, particularly the retrospective nature of this study,
a highly select group of patients, and relatively short me-
dian follow-up duration. Also, all procedures were per-
formed at a single center by two experienced surgeons
and included the entire scope of our practice (cases
requiring cardiopulmonary bypass) during the study
period. The approach to this retrospective study was to
include all cases requiring bypass (LVADs, transplants,
cardiac cases), although subgroup analysis (i.e. assist
device case, transplants, circulatory arrest cases, etc.) in
a future trial with larger numbers of patients will be
necessary. Multicenter prospective studies with longer
follow-up will further establish the clinical efficacy of
Arista® AH as a topical hemostatic agent in cardio-
vascular surgical procedures.ication. Note the presence of red blood cells and fibrin strands
ion (450×). B) High magnification (1900×).
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The application of Arista® AH during cardiothoracic proce-
dures resulted in a reduction in intraoperative hemostasis
time, decrease in postoperative blood loss, and reduced
need for blood product transfusion in the first 48 hours
following surgery. Additionally, there were no adverse
events associated with broad field coverage with Arista®
AH within the cardiothoracic cavity. Although a retro-
spective study, our findings suggest that Arista® AH
is safe and effective in reducing blood loss as an adjunct
topical hemostatic agent in complex cardiothoracic
surgical procedures.
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